New Treatment Options Reshape Care for Lower-Risk Myelodysplastic Syndromes
A Cleveland Clinic expert reviews how luspatercept, imetelstat, and mutation-guided therapy are changing management of low- and intermediate-risk MDS.
Summary
Myelodysplastic syndromes (MDS) are bone marrow disorders, more common with age, in which blood cells are made ineffectively. This educational review focuses on low- and intermediate-risk disease, where treatment aims to ease symptoms and reduce the need for red blood cell transfusions. Since 2020, luspatercept and imetelstat have joined older options such as erythropoiesis-stimulating agents and lenalidomide. Early use of some of these drugs, before transfusions are needed, may offer benefit. Thrombopoietin receptor agonists can help isolated low platelets, and antithymocyte globulin is favored for hypocellular MDS. Low-dose hypomethylating agents are an option but have not been shown to improve survival. IDH1 and IDH2 inhibitors can be used for the uncommon patients with those mutations. Despite these tools, MDS eventually progresses to higher-risk disease or acute myeloid leukemia in many patients.
Detailed Summary
Myelodysplastic syndromes (MDS) are clonal blood cancers that mainly affect older adults. Most patients are diagnosed with lower-risk disease, where the main problems are anemia, fatigue, and transfusion dependence rather than immediate leukemia risk. Choosing therapy well matters because patients may live with this disease for years.
This narrative review from the ASH Education Program summarizes current management of low- and intermediate-risk MDS. These patients have at least 10% dysplasia in one cell line, mild cytopenias, low marrow blasts, and an IPSS-M score of 0 or below. The author stresses that mutation profiling at diagnosis and over time helps with classification, prognosis, and treatment decisions.
The review highlights several points. Luspatercept and imetelstat, available since 2020, offer new ways to reduce red blood cell transfusion burden. Erythropoiesis-stimulating agents and lenalidomide remain useful for anemia and are usually started once transfusions are needed, though emerging data suggest earlier use could help. Thrombopoietin receptor agonists can treat isolated thrombocytopenia when blasts are low, and antithymocyte globulin is favored in hypocellular MDS. Dose-modified hypomethylating agents are an option, but neither overall nor progression-free survival has been shown to improve. IDH1 inhibitors are FDA approved for the rare IDH1-mutated MDS (under 10% of cases), and an IDH2 inhibitor is reasonable for IDH2-mutated disease (under 5%). IDH mutations appear more often in older patients and those with autoimmune or rheumatologic conditions.
The practical implication is a more individualized, genomics-informed approach aimed at symptom control and fewer transfusions. Even so, these therapies do not prevent eventual evolution to higher-risk MDS or acute myeloid leukemia.
Caveats: this analysis is based on the abstract only. The article is a narrative review, not a new trial, and the author discloses industry relationships with several manufacturers of these therapies.
Key Findings
- Luspatercept and imetelstat have been available since 2020 to reduce red blood cell transfusion burden in lower-risk MDS.
- Emerging data suggest starting ESAs or lenalidomide before transfusion dependence may offer clinical benefit.
- Dose-modified hypomethylating agents have not been shown to improve overall or progression-free survival in lower-risk MDS.
- IDH1 mutations occur in under 10% of MDS and IDH2 in under 5%, with targeted inhibitors available.
- Despite treatment, lower-risk MDS ultimately evolves into higher-risk MDS or acute myeloid leukemia.
Methodology
This is a narrative educational review from the ASH Education Program, written by a single expert author. It synthesizes existing evidence and clinical practice for lower-risk MDS rather than presenting new data. Only the abstract was available for this summary.
Study Limitations
Based on the abstract alone, so details on trial data, dosing, and sequencing are unavailable. As a narrative review, it is subject to author selection and interpretation, and the author reports financial ties to several drug manufacturers. Evidence for earlier intervention is described as emerging and not yet established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: